JHVEPhoto/iStock Editorial via Getty Images Novo Nordisk (NVO) announced Thursday that the U.S. Food and Drug Administration (FDA) declined to approve its once-weekly insulin product, insulin icodec, targeted at patients with diabetes mellitus (DM). Issuing a complete response letter, the regulator has requested information related to its manufacturing process andContinue Reading
A new study has linked the use of GLP-1 drugs and metformin to a lower risk of developing certain obesity-related cancers in patients with Type 2 diabetes. The study, which was published Friday on the JAMA Network Open website, showed that patients taking GLP-1 drugs or metformin showed a significantlyContinue Reading
aprott/iStock via Getty Images There could be an association between Novo Nordisk’s (NVO) popular anti-obesity therapy semaglutide and an eye disorder called NAION (nonarteritic anterior ischemic optic neuropathy), according to a small study published in the medical journal JAMA on Wednesday. The study showed that obese or overweight patients whoContinue Reading
Carolina Rudah Novo Nordisk (NVO) is up 2.1% in premarket trade after the company’s Wegovy weight loss treatment was approved in the world’s second-largest economy. It’s a big market for blockbuster drug. More than half of Chinese people age 18 and older are obese or overweight, according to China’s NationalContinue Reading
Devonyu A new peer-reviewed study suggested this week that GLP-1 drugs, popularly used for weight loss, are associated with a lower risk of dementia in older people with diabetes. The trial considered real-world data from Sweden using more than 88,000 patients aged 65 or older with type 2 diabetes mellitusContinue Reading
